Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Athenahealth Unveils AthenaInsight, Focuses On Opioid Abuse

Published 09/21/2016, 09:39 PM
Updated 07/09/2023, 06:31 AM
EW
-
ATHN
-
USNA
-
AMPH
-

athenahealth Inc. (NASDAQ:ATHN) recently introduced athenalnsight, a daily news hub which will keep track of the activities of 80,000 healthcare providers and 81 million ‘de-identified patients’. This will help share comprehensive information pertaining to the healthcare industry with a much broader audience.

With this launch, athenahealth is set to look into factors that are affecting the nation’s ‘high-performing health systems’ and ‘public health wellness’, thanks to threats from Zika, flu virus and opioid (a painkiller drug).

Notably, opioid abuse is a mounting problem in the U.S. and athenahealth has collaborated with the Centers for Disease Control and Prevention (CDC) to launch the ‘Guideline for Prescribing Opioids for Chronic Pain’ to deal with this crisis. In fact, the company, with its newly launched platform, plans to carry out detailed investigations, conduct expert interviews and study the varied aspects of the crisis (with the help of data-backed charts and relevant infographics).

Coming to share price movement, athenahealth gained a nominal 0.5% to close at $121.64 following the news.

Our Take

We believe athenaInsight will be the ideal platform to address the issue of ‘information asymmetries’ in the American healthcare industry. The latest development promises to provide a clear picture of healthcare industry data and leadership insights of the care givers which is expected to exclusively fortify the company’s position in the Healthcare & Information Technology (HCIT) market.

Notably, the HCIT market has gained much investor’s focus of late on its forecast to reach a worth of $228.7 billion by 2020, at a CAGR of 13.4% (Markets And Markets), a major positive for athenahealth.

athenahealth has already marked its prominence as an Electronic Health Record (EHR) usability leader. In fact, the company is enhancing its growth trajectory with a strong product portfolio, growing physician base, solid R&D focus and unique business model. In addition to these, the recent development is a significant milestone for the company in our view.

Zacks Rank & Key Picks

Currently, athenahealth has a Zacks Rank #3 (Hold).

Better-ranked stocks in the broader medical instrument sector include USANA Health Sciences Inc. (NYSE:USNA) , Edwards Lifesciences Corp (NYSE:EW) and Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



ATHENAHEALTH IN (ATHN): Free Stock Analysis Report

AMPHASTAR PHARM (AMPH): Free Stock Analysis Report

EDWARDS LIFESCI (EW): Free Stock Analysis Report

USANA HLTH SCI (USNA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.